Sino-German connection: multidimensional exchanges of two international conferences in Luohu, Shenzhen

2020-08-18 12:06:09 Guangzhou Gloryren Medical Technology Co., Ltd 45

Under the situation of COVID-19, Shenzhen Luohu Hospital Group attaches great importance to international exchanges and interdisciplinary cooperation, and has always maintained an advanced international vision as well as consistent academic pursuit. On July 16th and July 31st, two Sino-German video conferences were held with Department of Urology at the Universitätsklinikum Hamburg-Eppendorf and Hospital of the Ludwig-Maximilians-University Munich.

Sino-German Connection: Universitätsklinikum Hamburg-Eppendorf 

On July 16, Prof. SUN XiZhuo, President of Shenzhen Luohu Hospital Group, Prof. WU Song, Director of Shenzhen University Institute of Urology and Secretary of the Party Committee of Shenzhen Luohu Hospital Group attended and presided over the meeting. Prof. Fisch, Director of the Clinical and Comprehensive Clinic of Urology at Universitätsklinikum Hamburg-Eppendorf, and Senior Physician Prof. Rink, were invited to bring wonderful keynote lectures, and doctors from Department of Urology, Luohu Hospital Group also actively participated in meetings and provided case discussions.


Prof. SUN XiZhuo, President of Shenzhen Luohu Hospital Group, expressed his warmest welcome and sincere greetings to the two professors. He described the current development and achievements of the Luohu Hospital Group, and introduced Professor WU Song, who is the leading researcher in the study of the pathogenesis of bladder cancer in China.

Prof. Sun introduced that Shenzhen Luohu Hospital Group is a compact medical group, one of the models of China’s healthcare reform. It has 6 hospitals under its control, including Shenzhen Luohu Hospital of TCM, Shenzhen Luohu Hospital Group Luohu People’s Hospital, and Shenzhen Luohu District Maternal and Child Health Hospital; and 31 community medical service centers. It has about 5,000 employees, 2130 hospital beds. In 2019, the number of outpatient reached 3.5 million and discharged patients were about 70,000. The hospital provides internationally recognized and popular integrated medical services, and adheres to the medical reform goal of "less sickness, less hospitalization, less burden, and better treatment" for inhabitants.


Prof. Wu first of all gave a brief introduction to the Department of Urology of Shenzhen Luohu Hospital Group and the Institute of Urology of Shenzhen University.

Department of Urology of Shenzhen Luohu Hospital Group

Shenzhen Luohu Hospital Group Urology is now the leading unit which is demonstrated by the Director of the Shenzhen Medical Association, Shenzhen Urology Diagnosis and Quality Control Center and Shenzhen University Institute of Urology and the key specialty in Shenzhen. Equipped with a Da Vinci Xi Surgical System and other international first-class equipment, it has opened nearly 100 beds. There are 31 surgeons, 23 clinical researchers, 40 nurses, 1 national elite youth, 1 Medical Leading Talents of Guangdong Province, 23 PhD/M.D. and postdoctoral fellows, 1 doctoral supervisor, 3 post-doctoral supervisors and 5 master supervisors. It has three inpatient areas: the Hospital in Youyi Road is the Inpatient Areas No.1-2 and the Group Hospital of TCM in Liantang is the Inpatient Area No.3.Taking the lead in presiding over 1 National Key R&D Program of China, 1 The National Natural Science Foundation of China fund key project, 11 The National Natural Science Foundation of China fund, and 2 clinical cohort studies on the layout of major basic disciplines in Shenzhen.The hospital group has a core clinical and research team of five well-known experts in the field, including Professor YANG JiangGen, Director of Urology, Professor WU Song, Academic Pacesetter, Professor LI WeiDong, Professor HUANG GuiXiao and Professor LI HuiZhen, Deputy Director of the department. Sub-specialties have also been established: Dr. MOU Huang, Director of Urological Oncology Sub-specialty, Dr. LI BaoXing, Director of Andrology Department, Dr. HUANG Ying, Director of Pediatric Urology, Prof. DUAN QiLin, stone specialist , and Dr. HUANG RuiXu, Director of TCM Urology.


Prof. Fisch presented the overall situation and direction of the Universitätsklinikum Hamburg-Eppendorf and the Department of Urology, which cooperates with the largest prostate cancer center in the world.

Universitätsklinikum Hamburg-Eppendorf

Universitätsklinikum Hamburg-Eppendorf has 9,600 employees, of whom 2,400 are surgeons and 3,100 are nurses. The hospital has 42 operating rooms with 1,630 beds and a further 132 beds for intensive care, which increased to 175 during the COVID-19. The hospital receives about 92,000 inpatients and 291,000 outpatients per year.


In 2019, the Urology Department received 4,693 inpatients and performed 3,594 operations. The case-mix index (CMI) was 1.14, which is above of the average level in Germany. The department also cooperates closely with MARTINIKCINIC, the world's largest prostate cancer research institute: with 4 Da Vinci Si surgical systems, the department receives more than 5,000 outpatients, more than 750 prostate biopsies, more than 2,000 radical prostatectomies and more than 300 primary radiotherapy treatments per year. They are also able to maintain a scientific publication rate of one scientific paper per week.

In addition to covering urology-related cases, the Department of Urology specializes in reconstructive urology (more than 300 urethroplasty operations per year), paediatric urology (training centre of the European Association of Paediatric Urology) and oncology. Afterwards, Prof. Rink gave a lecture on "Precision Treatment of Bladder Cancer". Prof. Rink introduced that bladder cancer is a common disease, the second most common urinary system malignancy after prostate cancer, and the fourth most common malignant tumor in men. Radical cystectomy (RC) is now considered the standard treatment for muscle-invasive bladder cancer (MIBC) and recurrent, high-risk non-muscle-invasive bladder cancer (NMIBC) after failure of bladder perfusion chemotherapy.


According to the depth of invasion and metastasis of bladder cancer, the survival prognosis of patients with different TNM stages is quite different. And the study data pointed out that the recurrence rate of bladder cancer is high, and most of them recur after 12-24 years of treatment. Prof. Rink said to optimize the development of imaging tests to deepen the understanding of the pathology and progression of bladder cancer to improve the diagnosis of bladder cancer. On the therapeutic side, the professor shared the impact of neoadjuvant chemotherapy on the efficacy and survival in the treatment of muscle-invasive bladder cancer and introduced the detection of circulating tumor cells in blood.


Finally Prof. Rink concludes that bladder cancer is a complex disease with high genetic heterogeneity. Bladder cancer urgently needs precision medicine for more personalized and customized decision making and treatment options. Current precision medicine is all very promising. Some very meaningful molecular markers should also be included in clinical trials to improve the effectiveness of their clinical applications.


A case of prostate ductal adenocarcinoma was analyzed by Dr. Enpu Zhang, a urologist at Shenzhen Luohu Hospital.


Sino-German Connection: Urology Department at Ludwig-Maximilians-University Munich

Prof. Wu Song first introduced the Department of Urology at Shenzhen Luohu Hospital Group and the Group to Prof. Stief, who is the Head and Professor of the Department of Urology at Ludwig-Maximilians-University Munich. 


Prof. Stief introduced the Department of Urology at Ludwig-Maximilians-University Munich.


The Department of Urology at Ludwig-Maximilians-University Munich.

The Department of Urology at Ludwig-Maximilians-University Munich has a total of 97 beds plus some children's beds and ICU beds shared with other departments. There are five operating rooms for inpatients, two operating rooms for outpatients with anesthesia and six cystoscopy/biopsy rooms. The department also has 35.5 doctors (including part-time doctors who work half the hours).


The department performs 650 cases of transurethral prostatectomy/ Holmium laser prostatectomy, 550 cases of transurethral cystectomy, 300 cases of ureteroscopy + laser, 5 cases of extracorporeal shock wave lithotripsy, 620 cases of radical prostatectomy, 150 cases of radical cystectomy, 200 cases of partial nephrectomy for renal tumors, 70 cases of radical nephrectomy, 130 cases of open urethroplasty and 150 cases of urinary incontinence surgery.


This was followed by Prof. Stief's keynote lecture on the topic "Robotic-assisted radical and open radical prostatectomy for prostate cancer and patient post-operate health quality life report".


The Da Vinci Si surgical systems is regarded as the most powerful high-tech weapon in urology, and according to Prof. Stief, there are many surgeries in the Department of Urology at Ludwig-Maximilians-University Munich were done with the use of Da Vinci systems, which can be performed from morning to night, and Prof. Stief has a lot of experience in doing Da Vinci surgeries, and this time he brought us eye-opening data comparing open surgery (ORP) and robot-assisted radical prostatectomy (RARP).

This study collected 1500 patients who underwent radical prostatectomy in the Department of Urology at  Ludwig-Maximilians-University Munich from August 2013 to March 2018, including 750 cases of open radical prostatectomy and 750 cases of robotic-assisted radical prostatectomy. The two groups were matched by propensity score matching in a 1:1 ratio to ensure that there were no differences in tumor stage, age, prostate-specific antigens, and other factors between the two groups.


Finally, the data related to ORP and RARP are summarized as follows.

Probability of blood transfusion: similar.

Operation time: RARP>ORP.

Oncological findings: same.

Early incidence of urinary incontinence: ORP > RARP

Health-related quality of life scores and urinary incontinence questionnaire scores (GHS and ICIQ): ORP > RARP

Erectile function: same

Prof. WU Song was impressed by the eye-opening keynote lecture shared by Prof. Stief and looks forward to Prof. Stief's presentation of this research.


Prof. Stief had an in-depth discussion with urologists from Shenzhen Luohu Hospital Group about ICIQ scores for open surgery and robot-assisted surgery, and exchanged ideas with Prof. WU Song about the future application of the Da Vinci surgery system.

Dr. TAO Ran, a urologist from Shenzhen Luohu Hospital Group, gave a report on the epidemiological characteristics of urolithiasis patients in Shenzhen.


Prof. Stief also shared the experience of German hospitals in the prevention and control of recurrence of urinary stones, and the trends in the surgical treatment of urolithiasis in Germany.


At the end of the meeting, Prof. WU Song and the urologists from Luohu Hospital Group thanked Prof. Stief once again for taking the time to participate in the meeting and selflessly sharing the latest research data and valuable experience.


HOTLINE: 020-8928-7873 Hospital-centered and detail-oriented.